Electrophysiology has emerged as a central pillar in the intersection of neuroscience and the treatment of neuropsychiatric ...

VANCOUVER, Washington, Feb. 01, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for ...

- Single-dose administration of LAE102 by IV or SC injection demonstrated a favorable safety profile in the healthy participants as well as robust and prolonged target engagement in the healthy ...

The hormone estrogen regulates binge drinking in females, causing them to 'pregame' -- consume large quantities of alcohol in the first 30 minutes after it's offered, according to a preclinical study.

LYON, France--(BUSINESS WIRE)--Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases ...

In a multi-institutional study published today in Nature Nanotechnology, researchers from The University of Texas MD Anderson Cancer Center reported that engineered bispecific nanobodies successfully ...

Immune cells in the brain called microglia can partially break down large amyloid plaques characteristic of Alzheimer's disease by latching on to them, forming a sort of external stomach and releasing ...

A preclinical study published in Nature has found evidence that the hippocampus, the brain region that stores memory, also ...

– SL-325 is a high-affinity DR3 blocking antibody being developed for the treatment of inflammatory bowel disease (IBD); No evidence of toxicity or residual agonism observed in non-human primate ...

Silo Pharma, Inc. has announced the start of a pharmacokinetic and tolerability study for its novel, non-opioid extended-release pain therapeutic, SP-26, in collaboration with AmplifyBio. The study ...